Columnist Connie Chandler may have limited control over her physical abilities, but she can always strengthen her faith and ...

Leuprorelin acetate, a medicine approved in the U.S. for prostate cancer, may slow the progression of SMA type SBMA, ...

Discover the most-read SMA stories of 2025, featuring updates on the gene therapy Zolgensma, next-generation treatments, and ...

Columnist Connie Chandler offers a message of courage and hope for those spending this season in a hospital bed.

This Christmas, columnist Ari Anderson gives thanks that some health complications he experienced post-surgery resolved on ...

Columnist Brianna Albers is not good at waiting. One might say she's terrible at it. Living with SMA, though, seems to bring a lot of it.

A new review of studies reveals that incorporating SMA into newborn screening programs yields clinical improvements and reduces costs.

The gene therapy Zolgensma (onasemnogene abeparvovec-xioi) has been newly approved to treat patients with spinal muscular atrophy (SMA) through intravenous (IV) delivery, meaning systemically. However ...

After a “constructive and collaborative in-person” meeting with the U.S. Food and Drug Administration (FDA), Scholar Rock is now planning to once again seek approval of its muscle-strengthening agent ...

Children with spinal muscular atrophy (SMA) given the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) in infancy are maintaining motor milestones after up to a decade of follow-up, according to ...

For whatever reason, society loves to infantilize disabled people. It’s practically a hobby for some people, be they medical professionals or middle-aged pedestrians looking to test their comedy ...

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disorder characterized by progressive muscle weakness. SMA patients do not produce enough of a protein called survival motor neuron (SMN ...